title: [Optimization of thrombolytic treatment in acute myocardial infarct: the role of new fibrinoselective drugs and their combination with new antithrombotics].
abstract: Although reperfusion therapy is well recognized as the mainstay of treatment of acute myocardial infarction, mortality of myocardial infarction is still high, thrombolytic treatment remains underutilized and, usually, applied too late. Additionally, most of the patients do not experience optimal reperfusion because of the suboptimal flow rate in the infarct-related artery, abnormal microvascular flow, and reocclusion of the infarct-related artery. Strategies to enhance the results of reperfusion therapy include, expanding the population of potential candidates, earlier treatment, and newer methods to improve infarct-related artery flow rates. In this sense, new thrombolytic agents, and combination therapies with or without addition of more potent and specific new antithrombotic agents are being extensively investigated. Also, it is important to promote studies of ancillary treatments to reduce reperfusion injury, which may be one cause of decreased microvascular flow. Although aspirin and heparin have been the conventionally used agents for inhibiting thrombin and platelet function, newer agents such as hirudin or hirulog and inhibitors of the platelet glycoprotein IIb-IIIa receptors are becoming available, and their clinical application will increase in the future.
authors.affiliation: Institut de Malalties Cardiovasculars, Hospital Clínic, Universidad de Barcelona.
authors.forename: M
authors.initials: M
authors.lastname: Sitges
authors.forename: X
authors.initials: X
authors.lastname: Bosch
authors.forename: A
authors.initials: A
authors.lastname: Betriu
mesh_terms: D000208:Acute Disease; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*
chemical_list: D005343:Fibrinolytic Agents
vernacular_title: Optimización del tratamiento trombolítico en el infarto agudo de miocardio: papel de los nuevos fármacos fibrinoselectivos y de la asociación con los nuevos antitrombóticos.